Barclays Maintains Overweight on Replimune Group, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson has maintained an Overweight rating on Replimune Group (NASDAQ:REPL) but has reduced the price target from $50 to $13.

December 06, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained its Overweight rating on Replimune Group but significantly lowered the price target from $50 to $13.
The substantial reduction in price target from $50 to $13 by a major analyst like Barclays is likely to negatively impact investor sentiment and could lead to a short-term decline in Replimune Group's stock price. While the Overweight rating suggests a positive outlook on the stock, the drastic cut in the price target may overshadow this and cause concern among investors about the company's valuation or future prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100